S

Synlogic
D

SYBX

1.25000
USD
0.10
(8.70%)
مغلق
حجم التداول
0
الربح لكل سهم
-7
العائد الربحي
-
P/E
6
حجم السوق
14,620,136
أصول ذات صلة
A
ACAD
0.660
(2.98%)
22.810 USD
C
CRSP
1.580
(3.80%)
43.190 USD
E
EDIT
-0.02000
(-0.93%)
2.13500 USD
F
FATE
-0.03500
(-2.85%)
1.19500 USD
INCY
INCY
-2.450
(-3.44%)
68.770 USD
REGN
REGN
-13.79
(-2.64%)
508.86 USD
S
SAGE
0.04500
(0.50%)
9.11500 USD
S
SGMO
-0.01250
(-2.52%)
0.48260 USD
VRTX
VRTX
-8.77
(-1.95%)
442.01 USD
المزيد
الأخبار المقالات

العنوان: Synlogic

القطاع: Healthcare
الصناعة: Biotechnology
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformativetreatments for serious diseases.